Can You Now Get Mounjaro on the NHS? (October 2026)

01 · NHS access

Can you get Mounjaro on the NHS now?

Yes, but only if you fall into a group the rollout has reached. Mounjaro is available on the NHS, with access phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition. The primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁴⁶ Full rollout is expected to take years.

For the detail, see NHS qualification. If you have diabetes, read whether diabetics can get Mounjaro on the NHS.

02 · Comparison

NHS or private: which fits you?

Private treatment is clinically assessed too: a GPhC-registered prescriber reviews every order.¹ If you prefer not to wait, the Mounjaro pen is in stock across all six doses, with free next-day tracked delivery. Your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99), and every later order is £25 off the standard price. You can start your free consultation with no obligation, or compare all weight loss treatments.

03 · Who qualifies privately

Who qualifies for private treatment

Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition. Examples are high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. It must be used alongside a reduced-calorie diet and increased physical activity.¹

People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds are at higher risk of weight-related health problems at a lower BMI, so clinical thresholds are usually reduced by 2.5 kg/m² for these groups. A prescriber assesses your BMI, history and current medicines first. See the conditions that count for NHS access.

04 · Who should not take it

Who should not take Mounjaro

You should not take Mounjaro if you are allergic to tirzepatide or any of its ingredients, and it must not be used during pregnancy; stop it at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. Prescribers take extra care, or may advise against it, with a history of pancreatitis, severe digestive disease, diabetic retinopathy or gallbladder problems.¹

Tell your prescriber about any personal or family history of medullary thyroid cancer or MEN 2.¹³ This applies whether you are treated on the NHS or privately. Serious side effects are uncommon but need urgent attention. Seek immediate medical help for severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin or eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing.

05 · What results to expect

What results to expect

In SURMOUNT-1 (2,539 adults), people taking tirzepatide with diet and exercise lost on average 15% of body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, versus 3.1% with lifestyle changes alone.² For someone starting at 100 kg, 20.9% is about 21 kg. These are trial averages, and individual results vary.

06 · Devolved nations

Scotland, Northern Ireland and local areas

Local arrangements can differ, so check your area. See Mounjaro on NHS Scotland, Northern Ireland, Fife and Tayside. For a wider overview read what to know about NHS access in the UK.